Pityriasis lichenoides is an uncommon, acquired, papulosquamous disorder that exhibits various clinical presentations, including acute, chronic, and febrile ulceronecrotic Mucha- abermann forms. Pityriasis lichenoides chronica (PLC) is the chronic form of this continuum. Its treatment is challenging for patients and clinicians and some cases are multidrug resistant. Today, this disorder has many treatment choices, including topical corticosteroids, topical calcineurin inhibitors, phototherapy (ultraviolet (UV) A and narrow band UVB), methotrexate, dapsone, cyclosporine and recently etanercept. In our experience, mycophenolate mofetil was effective as a new treatment for pityriasis lichenoides.
Mozhdeh,S. and Zohreh,M. (2015). Is mycophenolate mofetil a new treatment for pityriasis lichenoides? A case report. Iranian Journal of Dermatology, 18(4), 179-181.
MLA
Mozhdeh,S. , and Zohreh,M. . "Is mycophenolate mofetil a new treatment for pityriasis lichenoides? A case report", Iranian Journal of Dermatology, 18, 4, 2015, 179-181.
HARVARD
Mozhdeh S., Zohreh M. (2015). 'Is mycophenolate mofetil a new treatment for pityriasis lichenoides? A case report', Iranian Journal of Dermatology, 18(4), pp. 179-181.
CHICAGO
S. Mozhdeh and M. Zohreh, "Is mycophenolate mofetil a new treatment for pityriasis lichenoides? A case report," Iranian Journal of Dermatology, 18 4 (2015): 179-181,
VANCOUVER
Mozhdeh S., Zohreh M. Is mycophenolate mofetil a new treatment for pityriasis lichenoides? A case report. Iran J Dermatol, 2015; 18(4): 179-181.
